EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study

Kosuke Ebina, Toru Hirano, Yuichi Maeda, Yasutaka Okita, Yuki Etani, Makoto Hirao, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Akira Onishi, Sadao Jinno, Ryota Hara und 9 weitere

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac092 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Kosuke Ebina und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Methotrexate, Antirheumatic Agents, Arthritis, Rheumatoid, Immunosuppressive Agents. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This multicenter, retrospective study evaluated the effectiveness of add-on methotrexate (MTX) or iguratimod (IGU) in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors (JAKis).

Methods

Forty-five patients were treated with new additional MTX (n = 22) or IGU (n = 23) and followed for 6 months. Patients’ background is as follows: age, 59.2 years; disease activity score of 28 joints with C-reactive protein (DAS28-CRP), 3.4; clinical disease activity index, 15.7; biological disease-modifying antirheumatic drug (DMARD)-switched cases, 77.8%; first JAKi cases, 95.6%; and JAKi treatment: tofacitinib (n = 25), baricitinib (n = 17), upadacitinib (n = 2), and peficitinib (n = 1) for 9.6 months.

Results

Thirty-five patients continued the combination therapy for 6 months without a significant change in concomitant glucocorticoid or other conventional synthetic DMARDs. DAS28-CRP (MTX, 3.6 to 2.6, p < 0.05; IGU, 3.3 to 2.1, p < 0.001) and clinical disease activity index (MTX, 16.7 to 8.8, p < 0.05; IGU, 14.6 to 6.5, p < 0.01) improved significantly from baseline. Using the 2019 European League Against Rheumatism criteria, 45.4% (MTX) and 39.1% (IGU) achieved moderate or good response and 40.9% (MTX) and 39.1% (IGU) achieved American College of Rheumatology 20% improvement criteria.

Conclusions

Adding MTX or IGU to inadequate responders of JAKi can be considered as a complementary treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateAntirheumatic AgentsArthritis, RheumatoidImmunosuppressive AgentsJanus Kinase InhibitorsHumansRetrospective StudiesSulfonamidesDrug Therapy, CombinationTreatment OutcomeMaleFemaleMiddle AgedAdultAgedAged, 80 and overChromones

Stichwörter der Autor:innen

IguratimodJanus kinase inhibitorinadequate responsemethotrexaterheumatoid arthritis

Substanzen

MethotrexateAntirheumatic AgentsSulfonamidesImmunosuppressive AgentsJanus Kinase InhibitorsiguratimodChromones

Autor:innen und Institutionen

  • Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Rheumatology, Nishinomiya Municipal Hospital, Hyogo, Japan.
  • Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.

Zitieren

APA

Ebina, K., Hirano, T., Maeda, Y., Okita, Y., Etani, Y., Hirao, M., Yamamoto, W., Hashimoto, M., Murata, K., Onishi, A., Jinno, S., Hara, R., Son, Y., Amuro, H., Kotani, T., Shiba, H., Katayama, M., Yamamoto, K., Kumanogoh, A., …, & Nakata, K. (2023). Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roac092

Vancouver

Ebina K, Hirano T, Maeda Y, Okita Y, Etani Y, Hirao M, et al. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study. Modern Rheumatology. 2023. doi:10.1093/mr/roac092

BibTeX
@article{Ebina2023,
  author = {Ebina, Kosuke and Hirano, Toru and Maeda, Yuichi and Okita, Yasutaka and Etani, Yuki and Hirao, Makoto and Yamamoto, Wataru and Hashimoto, Motomu and Murata, Koichi and Onishi, Akira and Jinno, Sadao and Hara, Ryota and Son, Yonsu and Amuro, Hideki and Kotani, Takuya and Shiba, Hideyuki and Katayama, Masaki and Yamamoto, Keiichi and Kumanogoh, Atsushi and Okada, Seiji and Nakata, Ken},
  title = {Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac092}
}
Kostenlos starten →